MA54379A - Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant - Google Patents
Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenantInfo
- Publication number
- MA54379A MA54379A MA054379A MA54379A MA54379A MA 54379 A MA54379 A MA 54379A MA 054379 A MA054379 A MA 054379A MA 54379 A MA54379 A MA 54379A MA 54379 A MA54379 A MA 54379A
- Authority
- MA
- Morocco
- Prior art keywords
- mcl
- inhibitor
- preparation
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306634 | 2018-12-06 | ||
| PCT/EP2019/083773 WO2020115183A1 (fr) | 2018-12-06 | 2019-12-05 | Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54379A true MA54379A (fr) | 2021-10-13 |
| MA54379B1 MA54379B1 (fr) | 2023-12-29 |
Family
ID=64665802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54379A MA54379B1 (fr) | 2018-12-06 | 2019-12-05 | Nouvelles formes cristallines d'un thienopyrimidine inhibiteur de mcl-1 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12129261B2 (fr) |
| EP (1) | EP3891156B1 (fr) |
| JP (1) | JP7649241B2 (fr) |
| KR (1) | KR102855345B1 (fr) |
| CN (1) | CN113166169A (fr) |
| AR (1) | AR117255A1 (fr) |
| AU (1) | AU2019391329B2 (fr) |
| BR (1) | BR112021010072A2 (fr) |
| CA (1) | CA3121363A1 (fr) |
| DK (1) | DK3891156T3 (fr) |
| EA (1) | EA202191534A1 (fr) |
| ES (1) | ES2971258T3 (fr) |
| FI (1) | FI3891156T3 (fr) |
| HR (1) | HRP20240211T1 (fr) |
| HU (1) | HUE065266T2 (fr) |
| IL (1) | IL283656B2 (fr) |
| LT (1) | LT3891156T (fr) |
| MA (1) | MA54379B1 (fr) |
| MD (1) | MD3891156T2 (fr) |
| MX (1) | MX2021006702A (fr) |
| PL (1) | PL3891156T3 (fr) |
| PT (1) | PT3891156T (fr) |
| RS (1) | RS65047B1 (fr) |
| SI (1) | SI3891156T1 (fr) |
| TW (1) | TWI905090B (fr) |
| WO (1) | WO2020115183A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7900421B2 (ja) | 2021-06-11 | 2026-08-04 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ |
| TWI861509B (zh) | 2021-06-11 | 2024-11-11 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2019
- 2019-12-05 US US17/295,521 patent/US12129261B2/en active Active
- 2019-12-05 BR BR112021010072-5A patent/BR112021010072A2/pt unknown
- 2019-12-05 RS RS20240001A patent/RS65047B1/sr unknown
- 2019-12-05 HU HUE19817229A patent/HUE065266T2/hu unknown
- 2019-12-05 FI FIEP19817229.8T patent/FI3891156T3/fi active
- 2019-12-05 HR HRP20240211TT patent/HRP20240211T1/hr unknown
- 2019-12-05 PT PT198172298T patent/PT3891156T/pt unknown
- 2019-12-05 CA CA3121363A patent/CA3121363A1/fr active Pending
- 2019-12-05 EP EP19817229.8A patent/EP3891156B1/fr active Active
- 2019-12-05 AU AU2019391329A patent/AU2019391329B2/en active Active
- 2019-12-05 CN CN201980080579.8A patent/CN113166169A/zh active Pending
- 2019-12-05 WO PCT/EP2019/083773 patent/WO2020115183A1/fr not_active Ceased
- 2019-12-05 EA EA202191534A patent/EA202191534A1/ru unknown
- 2019-12-05 KR KR1020217020808A patent/KR102855345B1/ko active Active
- 2019-12-05 MD MDE20210991T patent/MD3891156T2/ro unknown
- 2019-12-05 ES ES19817229T patent/ES2971258T3/es active Active
- 2019-12-05 AR ARP190103554A patent/AR117255A1/es unknown
- 2019-12-05 PL PL19817229.8T patent/PL3891156T3/pl unknown
- 2019-12-05 MX MX2021006702A patent/MX2021006702A/es unknown
- 2019-12-05 IL IL283656A patent/IL283656B2/en unknown
- 2019-12-05 MA MA54379A patent/MA54379B1/fr unknown
- 2019-12-05 TW TW108144437A patent/TWI905090B/zh active
- 2019-12-05 LT LTEPPCT/EP2019/083773T patent/LT3891156T/lt unknown
- 2019-12-05 JP JP2021531796A patent/JP7649241B2/ja active Active
- 2019-12-05 DK DK19817229.8T patent/DK3891156T3/da active
- 2019-12-05 SI SI201930704T patent/SI3891156T1/sl unknown
-
2024
- 2024-09-24 US US18/894,074 patent/US20250011337A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3862348A4 (fr) | Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée | |
| EA202190356A1 (ru) | Композиции и способы лечения расстройств, ослабляемых активацией мускариновых рецепторов | |
| EP3699174A4 (fr) | Composition pour la prévention ou le traitement de maladies liées au tnf, contenant un nouveau dérivé en tant que principe actif, et procédé d'inhibition de l'activité du tnf à l'aide de celle-ci | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| EP3349762A4 (fr) | Co-cristaux d'inhibiteurs de sglt2, procédé pour leur préparation et compositions pharmaceutiques de ceux-ci | |
| CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
| EP3502105A4 (fr) | Forme polymorphe d'un composé inhibiteur de kinase, composition pharmaceutique le contenant, son procédé de préparation et son utilisation | |
| EP3373932A4 (fr) | Forme cristalline d'un composé de quinoline substituée et composition pharmaceutique en contenant | |
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| EP3325456A4 (fr) | Formes cristallines du chlorhydrate de tétra-hydro-n,n-diméthyl-2,2-diphényl-3-furane-méthanamine, procédés de préparation desdites formes, et compositions pharmaceutiques les contenant | |
| EP3773900A4 (fr) | Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci | |
| EP3594216A4 (fr) | Composé hétérocyclique à cinq chaînons d'aminopyrimidine, intermédiaire, procédé de préparation, composition pharmaceutique et application de celui-ci | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| EP3946277A4 (fr) | Compositions pharmaceutiques orodispersibles d'apixaban | |
| AR072611A1 (es) | Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne. | |
| EP3485886A4 (fr) | Composition pharmaceutique de tecovirimat à administration orale et sa méthode de préparation | |
| MA54063A (fr) | Nouveau sel d'un inhibiteur de bcl-2, forme cristalline associée, son procédé de préparation et compositions pharmaceutiques le contenant | |
| MA54541A (fr) | Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées | |
| EA202190452A1 (ru) | Ингибиторы cdk8/19 | |
| EP4159235A4 (fr) | Composition pharmaceutique contenant un agoniste de pd-1 pour traiter ou prévenir une maladie médiée par th2 | |
| EP3603647A4 (fr) | Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d'adénosine | |
| EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
| MA53900A (fr) | Nouveaux dérivés d'amino-pyrimidonyl-pipéridinyl, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| EP3817744A4 (fr) | Formes d'ivosidénib et compositions pharmaceutiques |